Health Care·Pharmaceuticals·$153.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $0.61 | N/A | -1.61% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $0.61 | N/A | -1.61% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the difficulties faced in the current market environment. They did not offer any updates on future performance expectations.
Management expressed concerns about market conditions affecting performance.
They highlighted ongoing challenges in product sales.
No specific guidance was provided for future quarters.
Pfizer's earnings report indicates a slight miss on EPS, which contributed to a 2.02% decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's future performance. The defensive tone from management suggests they are cautious about market conditions moving forward.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
MONOLITHIC PWR SYS I
Oct 31, 2016